Dear Colleague, The event brochure has just been released and you can see it for yourself here. < span style="font-size: 10pt;"> My research with over 60 leading drug developing companies, has revealed the key challenges holding back progress for the industry in delivering personalized medicines to market. With input from key biomarker, diagnostic and commercial specialists from organizations such as Novartis, Roche, AstraZeneca, Pfizer, J&J, Eli Lilly and Medco I’ve put together the 4th World Companion Diagnostics Summit. 35 leading authorities in personalized medicine will be sharing their insights at the meeting over the 3 days, including: - Dr Vijay Modur, Head, Diagnostic Discovery, Novartis
- Richard Schatzberg, Co-Founder, President & Chief Executive Officer, Generation Health
- Dr Finley Austin, Personalized Healthcare & Biomarker Strategy Director, Astra Zeneca
- Dr David Geho, Senior Biomarker & Experimental Medicine Leader, Roche
- Dr Mitch Raponi, Senior Director, Molecular Diagnostics and Translational Medicine, Clovis Oncology
- Dr Carol Pena, Associate Director, Oncology Biomarkers, Bayer
- Dr Robert Beckman, Executive Director, Clinical Development Oncology, Daiichi Sankyo
- Dr Troyen Brennan, Executive Vice President & Chief Medical Officer, CVS Caremark
- Dr Ian Taylor, Senior Director, Translational Oncology, Pfizer
- Scott Taylor, Executive Director, Industry Relations, Geisinger Health System
- Dr Amy Miller, Public Policy Director, Personalized Medicine Coalition
- Dr Jeffrey Fill, Director, Clinical Diagnostics Laboratory, Eli Lilly
- Dr G. Mike Makrigiorgos, Associate Professor of Radiation Oncology, Dana-Farber Cancer Institute, Harvard
- Dr Jorge Villacian, Integrative Solutions Leader in Infectious Diseases, Janssen Pharmaceuticals (a company of Johnson & Johnson)
- Dr Donald Chalfin, Medical Director, Health Economics & Outcomes Research, Abbott
- Dr Leonard Reyno, Chief Medical Officer, Oncology, Astellas Pharma
| The full speaker line up can be viewed here. In the meantime, here’s the full list of organizations participating on the agenda so far:
Novartis – Pfizer – Eli Lilly – Roche – Johnson & Johnson – GSK – Daiichi Sankyo – Abbott – AstraZeneca – Transgene – Merck – MedImmune – Eisai – Janssen Pharmaceuticals – Astellas – Bayer – Clovis Oncology – Generation Health – CVS Caremark – Medco – Geron – Asuragen – Morphotek – Dana Faber Cancer Institute, Harvard – MIT – Phadia – Pangaea Biotech – Geisinger – Genetic Alliance – Personalized Medicine Coalition Here’s a snapshot of some of the key topics we’ll be looking for answers to at the meeting : - Where are we now with the development, approval and commercialization of companion diagnostics? What are the different patient stratification strategies companies are taking, both in large pharma and smaller drug developing companies?
- How do you successfully translate treatment stratification markers from bench to bedside and move from a research grade assay towards a clinically useful diagnostic test?
- How do you take a biomarker test from clinical validation to commercialization?
- Should you invest in in-house development or outsource? Should you develop LDTs or IVDs? What are the benefits and challenges associated with both prospective and retrospective biomarker development and in defining biomarker positive and negative patient populations?
- Understand the latest FDA guidance and its impact on your research and development of stratified medicines
- What does the reimbursement landscape of companion diagnostics look like and how do you achieve a positive reimbursement decision?
- How do we articulate the value of companion diagnostics to the wider healthcare community and drive adoption?
These are just a few of the key questions we’ll be addressing at the meeting. Full details of all topics for discussion over the 3 day meeting can be viewed in the event brochure. Hear from just a few of our previous attendees: “The best molecular dx meeting I have attended in several years” VP, Translational Oncology, Pfizer “An excellent view of the landscape with well integrated content from pharma, dx, clinical research and agency perspectives. This has been one of the best commercial meetings I have attended in memory” Advanced Cell Diagnostics “The event has been very valuable. A great conference to be informed of importance and current issues related to cdx/mdx. I am very glad I chose to attend as it has been a wealth of information” Immunogen
“This was my first conference I have attended by Hanson Wade - great job! The people made this conference extraordinary” PricewaterhouseCoopers “One of the best meetings I’ve attended. Outstanding!” Director, Merck “An intimate session where Rx meets Dx and vice versa. Very informative in terms of Rx vs. Dx perspectives” Director, Dako
| Visit the testimonials page for more feedback from our Personalised Medicine series of events. And what’s more, we have a special discounted rate for the first 50 people to sign up to the meeting. This would entitle you to up to 500 USD off standard prices. So don’t delay to secure the best rates. To take up one of these limited spaces: Call: +1 212 537 5898 Remember the discounted rate will expire after the first 50 registrants If you have any questions, don’t hesitate to get in touch. I look forward to meeting y ou on site in November. Best wishes, Janine Janine Bur rows Program Director Hanson Wade | |
A) Bridging the Gap: Co-Development of Targeted Therapeutics and Companion Diagnostics with FDA Sabah Malek, Senior Regulatory Scientist, Voisin Consulting Life Sciences Eric Lawson, Vice President, Compliance & Regulatory Affairs, Metamark Genetics
B) How Molecular Diagnostics will Affect Pharma Business Models and How to Keep Up Dr Keith Batchelder, Founder & CEO, Genomic Healthcare Strategies Peter Miller, Chief Operating Officer, Genomic Healthcare Strategies OR C) Stratified Medicine: Commercial Opportunities, Competitive Advantage and R&D Challenges Mark Trusheim, Visiting Scientist & Executive-in-Residence, MIT Sloan School of Managements
D) Accessing the Capabilities Required for Companion Diagn ostics Development and Commercialization through Strategic Partnerships Dr John Bloom, President, Bloom Consulting Services & Special Government Employee, FDA OR E) Commercial Return on Companion Diagnostics: Strategies and Tactics for Market Access, HTA, Pricing , Coverage, and Payment Patrick Terry, Partner & Principal, Pricing, Reimbursement & Market Access, Scientia Advisors
|
